Current neoadjuvant treatment options for HER2 positive breast cancer
Hikmat Abdel-Razeq, Lina MareiSection of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman, JordanAbstract: Approximately one quarter of patients with breast cancer demonstrate amplification of the human epidermal receptor type 2 (HER2) gene, the exp...
Enregistré dans:
Auteurs principaux: | Abdel-Razeq H, Marei L |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2011
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/fc642340cbf748b88e9d594db1cc3e9c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
par: Advani P, et autres
Publié: (2015) -
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
par: G. Griguolo, et autres
Publié: (2021) -
Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
par: Ho Hyun Ryu, et autres
Publié: (2021) -
Bevacizumab in the treatment of HER2-negative breast cancer
par: Vito Lorusso
Publié: (2008) -
Role of pertuzumab in the treatment of HER2-positive breast cancer
par: Hubalek M, et autres
Publié: (2012)